

REPORT DOCUMENTATION PAGE

AD-A221 536 COPY 1

1a. REPORT SECURITY CLASSIFICATION
 Unclassified

1b. RESTRICTIVE MARKINGS

AD-A221 536

3. DISTRIBUTION/AVAILABILITY OF REPORT
 Approved for public release;
 distribution is unlimited

2b. DECLASSIFICATION AUTHORITY

5. MONITORING ORGANIZATION REPORT NUMBER(S)

4. PERFORMING ORGANIZATION REPORT NUMBER(S)
 NMRI 90-18

6a. NAME OF PERFORMING ORGANIZATION
 Naval Medical Research

6b. OFFICE SYMBOL
 (if applicable)

7a. NAME OF MONITORING ORGANIZATION
 Naval Medical Command

6c. ADDRESS (City, State, and ZIP Code)
 Bethesda, Maryland 20814-5055

7b. ADDRESS (City, State, and ZIP Code)
 Department of the Navy
 Washington, D.C. 20372-5120

8a. NAME OF FUNDING/SPONSORING ORGANIZATION
 Naval Medical Research and Development Command

8b. OFFICE SYMBOL
 (if applicable)

9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER

8c. ADDRESS (City, State, and ZIP Code)
 Bethesda, Maryland 20814-5055

| 10. SOURCE OF FUNDING NUMBERS | | | |
|-------------------------------|-------------|----------|-------------------------|
| PROGRAM ELEMENT NO. | PROJECT NO. | TASK NO. | WORK UNIT ACCESSION NO. |
| 63706N | MM0095.003 | 1007 | DN677130 |

11. TITLE (Include Security Classification)
 Genetic analysis of the presentation of minor lymphocyte-stimulating determinants: II. Differing non-MHC control of super-stimulatory and more poorly stimulatory Mls phenotypes

12. PERSONAL AUTHOR(S) Ryan JJ, LeJeune HB, Mond JJ, Finkelman FD

13a. TYPE OF REPORT
 journal article

13b. TIME COVERED
 FROM _____ TO _____

14. DATE OF REPORT (Year, Month, Day)
 1990

15. PAGE COUNT
 12

16. SUPPLEMENTARY NOTATION Reprinted from: The Journal of Immunology 1990 April 1, Vol. 144 No. 7 pp. 2506-2517

| 17. COSATI CODES | | |
|------------------|-------|-----------|
| FIELD | GROUP | SUB-GROUP |
| | | |
| | | |
| | | |

18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number)
 Mixed lymphocyte reaction (MLR); Modifier genes;
 Minor lymphocyte stimulating (Mls) determinants; T cell growth factor; Non-major histocompatibility complex (MHC) genes

19. ABSTRACT (Continue on reverse if necessary and identify by block number)

DTIC
 ELECTE
 MAY 03 1990
 S D & D

20. DISTRIBUTION/AVAILABILITY OF ABSTRACT
 UNCLASSIFIED/UNLIMITED SAME AS RPT. DTIC USERS

21. ABSTRACT SECURITY CLASSIFICATION
 Unclassified

22a. NAME OF RESPONSIBLE INDIVIDUAL
 Phyllis Blum, Information Services Division

22b. TELEPHONE (Include Area Code)
 202-295-2188

22c. OFFICE SYMBOL
 ISD/ADMIN/NMRI

GENETIC ANALYSIS OF THE PRESENTATION OF MINOR LYMPHOCYTE-STIMULATING DETERMINANTS

II. Differing Non-MHC Control of Super-Stimulatory and More Poorly Stimulatory Mls Phenotypes¹

JOHN J. RYAN,^{2*} H. BALTZER LEJEUNE,* JAMES J. MOND,[†] AND FRED D. FINKELMAN[†]

From the *Immunobiology and Transplantation Department, Naval Medical Research Institute, Bethesda, MD 20814-5055, and [†]Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814-4799

Analysis of the capacity of splenocytes from non-prototypic Mls^d or Mls^e mouse strains to stimulate allogeneic H-2^k-compatible T cells in a primary Mls-defined MLR provided interesting examples of exceptions to the usually stated characterization of Mls^d and Mls^e determinants as highly stimulatory or weakly stimulatory, respectively. Across the Mls^a barrier, MA/My stimulator cells had a significantly reduced capacity to elicit responder proliferation in comparison with prototypic AKR/J or less well studied C58/J, CE/J, or RF/J splenocytes. Across the Mls^c barrier, a gradient of stimulatory ability was observed with RF/J splenocytes being virtually non-stimulatory, prototypic C3H/HeJ splenocytes having an intermediate capacity, and CE/J and C58/J being highly stimulatory presenters of this non-MHC specificity. The differing capacity of each of these H-2^k stimulator cells to elicit unprimed responder cell proliferation across an Mls^a or Mls^c difference correlated with the T cell growth factor activity that was secreted into the MLR supernatants. The super-stimulatory form of Mls^c was expressed in an autosomal dominant fashion by (Mls^c poorly stimulatory × Mls^c super-stimulatory)_{F1} animals, (BALB.K × C58/J)_{F1} or (RF/J × CE/J)_{F1}. The segregation of Mls^c stimulatory ability among first backcross and F₂ animals derived from the former F₁ was compatible with a single non-MHC gene controlling the expression and presentation of the super-stimulatory form of Mls^c. The regulatory nature of this gene was indicated by the observation that F₁ animals generated from the Mls^c nonprototypic and poorly stimulatory BALB/c parental strain were self-tolerant to

the super-stimulatory form of Mls^c. The existence of an Mls specificity other than a and c was suggested by positive non-MHC MLR responses in certain responder/stimulator cell combinations of Mls prototypic and nonprototypic mouse strains.

It has been known for over 20 years that murine non-MHC-encoded gene products, termed Mls³ determinants, presented by lymphoid stimulator populations, can trigger naive H-2-compatible allogeneic T cells to proliferate in a primary MLR (1). Recent genetic studies have shown that the Mls system is not comprised of a single locus as originally (2, 3) proposed; at least two unlinked Mls specificities, Mls^a and Mls^c, exist (4). In addition, the Mls^d moiety has been shown to represent the simultaneous expression of both Mls^a and Mls^c determinants (5-7). Some inbred mouse strains, originally typed as Mls^a or Mls^b, have been shown to encode Mls^c (8-11). Further studies also suggest that multiple genes may control the stimulation across an Mls^a (12) or an Mls^c (13-15) barrier.

Interestingly, the expression of certain TCR Vβ gene products is strongly associated with T cell responsiveness to certain Mls gene products (14, 16, 17). Mature thymocytes and peripheral T cells in Mls^a-bearing mice of an appropriate MHC haplotype were deleted of Vβ8.1⁺ (16) or Vβ6⁺ (18) TCR whereas these cell types obtained from Mls^c-bearing mice were deleted of Vβ3⁺ (14, 17, 19) TCR.

However, only the self-deleting Mls^a super-Ag has been considered highly stimulatory, with large numbers of CD4⁺ (20) T cells from H-2-compatible Mls^a-negative mouse strains precommitted to proliferate to this non-MHC moiety. In contrast, the Mls^c specificity has been routinely regarded as poorly to intermediately stimulatory (2-7, 10, 14, 15, 18, 21-35), with one study also suggesting that the precursor frequency of Mls^c-specific T cells in a heterogeneous T cell population is low (10).

This laboratory has recently shown that multiple non-MHC immune response genes significantly influence the presentation of Mls^c gene products expressed on splenic stimulator cells with permissive class II MHC restriction elements (8). In the present study we extend the latter investigation by the analysis of the primary MLR-stimulatory potential of Mls^a and Mls^c determinants expressed on splenic stimulator cells from poorly studied, nonprototypic, Mls-bearing mouse strains. By obtaining a more

Received for publication September 8, 1989.

Accepted for publication January 5, 1990.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ This work was supported by Naval Medical Research and Development Command Task No. M0095.003.1007 and by Grants R08308 (Uniformed Services University of Health Sciences), and R01-A121328 (National Institutes of Health). The opinions and assertions contained herein are the private ones of the authors and are not to be construed as official or reflecting the views of the Navy Department or the naval service at large. The experiments reported herein were conducted according to the principles set forth in the current edition of the "Guide for the Care and Use of Laboratory Animals," Institute of Laboratory Animal Resources, National Research Council.

² Address correspondence and reprint requests to John J. Ryan, Ph.D., Naval Medical Research Institute, Mail Stop 18, Naval Medical Command, National Capital Region, Bethesda, MD 20814-5055.

³ Abbreviations used in this paper: Mls, minor lymphocyte stimulating; GaMD, goat anti-mouse IgD antibody.

comprehensive understanding of the true variation in Mls^a and Mls^c-stimulatory capacity with nonprototypic mouse strains we attempt: a) to bring experimental scrutiny to the commonly held view regarding differences in MLR-stimulatory potential between Mls^a and Mls^c, b) to probe for additional underlying features of non-MHC genetic regulation of these moieties, and c) to search for heretofore unidentified non-MHC MLR-stimulatory specificities and possible members of the Mls "family" of determinants in poorly studied H-2-compatible responder/stimulator combinations.

MATERIALS AND METHODS

Animals. AKR/J (H-2^k, Mls^a), (AKR/J × DBA/2)F₁ (H-2^{k/d}, Mls^{a/c}), (BALB/c × DBA/2)F₁ (H-2^d, Mls^{a/c}), (BALB/cbyJ × DBA/2)F₁ (H-2^d, Mls^{a/c}), B10.BR (H-2^k, Mls^b), B10.D2 (H-2^d, Mls^b), CBA/J (H-2^k, Mls^{a/c}), CE/J (H-2^k, Mls^{a/c}), C3H/HeJ (H-2^k, Mls^c), (C57BL/6 × DBA/2)F₁ (H-2^{b/d}, Mls^{b/a/c}), C57BL/10Sn (H-2^b, Mls^b), C58/J (H-2^k, Mls^{a/c}), MA/My (H-2^k, Mls^a), RF/J (H-2^k, Mls^{a/c}), and SJL/J (H-2^s, Mls^g) mice were obtained from The Jackson Laboratory, Bar Harbor, ME. (AKR/J × BALB/c)F₁ (H-2^{k/d}, Mls^{a/c}), (AKR/J × B10.D2)F₁ (H-2^{k/d}, Mls^{a/b}), (AKR/J × C3H)F₁ (H-2^k, Mls^{a/c}), (BALB.K × C58)F₁ (H-2^k, Mls^{a/c}), (B10.BR × C58)F₁ (H-2^k, Mls^{b/a/c}), (B10.BR × RF/J)F₁ (H-2^k, Mls^{b/a/c}), (CBA/N × C3H)F₁ (H-2^k, Mls^{null/c})F₁, and (CBA/N × C58)F₁ (H-2^k, Mls^{null/a/c}) mice were bred at the Naval Medical Research Institute with parental breeding stock purchased from The Jackson Laboratory with the exception of BALB.K (H-2^k, Mls^c) mice that were kindly provided by Dr. Florence Rollwagen. Because it is likely that both Mls^a (12) and Mls^c (13-15) represent the products of multiple genes, the original small case letter designations for Mls specificities have been utilized throughout this study as collective symbols for these groups of multi-gene products. Experiments were performed with 8- to 20-wk-old animals that were maintained in filtered air isolators in the animal colonies of the Naval Medical Research Institute.

MLR. Responder cells for the MLR were obtained by enriching for T cells by passage of splenocytes over a nylon wool column according to the method of Julius et al. (36). Unprimed responder T cells were cultured at density of 3×10^5 cells/microtiter well, usually with 1.5 to 9×10^5 stimulator cells in a total volume of 0.2 ml. The MLR culture medium consisted of RPMI 1640 (Hazelton Laboratories, Lenexa, KA) with gentamicin (50 µg/ml), L-glutamine (2 mM), HEPES buffer (25 mM), 5% FCS (HyClone, Ogden, UT), and 5×10^{-5} M 2-ME. Each MLR was performed with quadruplicate cultures in round bottomed microculture plates (No. 3799; Costar, Cambridge, MA) and was maintained in a humidified atmosphere of 5% CO₂ at 37°C. The culture was harvested after 72 to 108 h onto glass fiber filter paper after a 12-µ pulse with $1 \mu\text{Ci}$ (37 kBq)/microtiter well of [³H]TdR (specific activity = 2 Ci/mM, New England Nuclear, Boston, MA). Incorporated [³H]TdR was measured on a Beckman scintillation spectrometer. The results were calculated from uptake of [³H]TdR and are expressed as the arithmetic mean in cpm of quadruplicate cultures. The SE were generally less than 10% of the mean. The χ^2 test was used to compare observed and expected MLR data in the first backcross and F₂ segregation analysis.

Assay of T cell growth factor activity in MLR supernatants. HT-2 cells (4×10^3), resuspended in MLR medium (see above), were added to flat bottom microtiter dishes (No. 76-032-05; Linbro, McClean, VA) together with serial dilutions of 48-h supernatants from Mls-defined MLR or known recombinant cytokines, in quadruplicate cultures; the total volume per culture well was 0.1 ml. These microtiter dishes were maintained at 37°C in a humidified atmosphere with 5% CO₂ for 24 h; a pulse of $1 \mu\text{Ci}$ /well of [³H]TdR was added during the last 6 h of culture before harvest. Incorporated [³H]TdR was measured as indicated above. The HT-2 cell line has been reported to be responsive to IL-2, IL-4, and granulocyte-macrophage CSF (37). However, this cell line, after maintenance at this institute for 2 yr, retained responsiveness only to IL-2 and IL-4 as demonstrated with the appropriate recombinant murine cytokine reagents obtained from Genzyme (Boston, MA) (data not shown).

In vivo anti-IgD treatment and in vitro preparation of MLR stimulator cells. Recipient mice were injected i.v. with 100 µg of affinity-purified GaMD in a volume of 0.2 ml, prepared as previously described (38). Twenty-four hours later the spleens were removed and were gently teased in HBSS with 10% FCS, were irradiated with 3000 R (¹³⁷Cs) after the removal of the RBC with a hypotonic lysing buffer, were washed again in HBSS with 10% FCS, and were resuspended in the MLR medium described above. This laboratory has shown that in vivo (24, 33, 39) or in vitro (39) activation of splenic T cells with GaMD before irradiation substantially enhances the

capacity to present both Mls specificities. When mitomycin C (85,549.9; Aldrich Chemical Co., Milwaukee, WI) was used instead of irradiation to prevent normal (non-GaMD-treated) splenic stimulator cells from dividing in the primary MLR, these splenocytes (1×10^7 /ml) were suspended in HBSS and were exposed to mitomycin C (75 µg/ml) for 30 min at 37°C in the absence of light and were then washed three times before being added to the responder T cells.

T cell depletion of splenocyte populations. Spleens were gently teased in RPMI 1640 plus 10% FCS, depleted of RBC with ammonium chloride lysing buffer, washed twice, and filtered through sterile nylon mesh (HC3-110; Tetco, Elmsford, NY) to remove tissue clumps. The single cell preparation was then suspended in monoclonal anti-Thy-1.2 ascites fluid (NEI-001, New England Nuclear Research Products, Boston, MA) at 1/500 dilution for ½ h at 4°C. The treated cells were then washed twice and resuspended in a 1/8 dilution of rabbit C (ACL 3051, Low-Tox M, Accurate Chemical and Scientific Corp., Westbury, NY) for 45 min at 37°C. The remaining splenocytes were washed twice and again passed through sterile nylon mesh to remove dead cells and tissue debris before treatment with mitomycin C (see above).

RESULTS

Wide variation in Mls^a- and Mls^c-presenting capacity exists with stimulator cells obtained from different H-2^k-compatible mouse strains. In order to test the commonly accepted belief, based on the examination of certain prototypic mouse strains, that Mls^a and Mls^c determinants were highly or poorly to intermediately stimulatory, respectively, splenocytes from other less well studied H-2^k mouse strains were analyzed for their Mls^a and Mls^c presenting capacity in a primary MLR.

Whether normal (nonactivated) mitomycin C-treated splenocytes (Table I, experiment 1) or in vivo GaMD-activated irradiated splenocytes (Table I, experiment 2) were used as stimulator cells, both the Mls^c determinants detected by Mls^a AKR/J T cells and the Mls^a determinants detected by Mls^c C3H/HeJ T cells on C58/J stimulator cells elicited very potent levels of responder cell proliferation that were approximately equivalent. Consistent with the finding that both Mls^a and Mls^c determinants were expressed on C58/J splenocytes was the observation that H-2-compatible Mls^{a/c} (AKR × C3H)F₁ responder cells did not proliferate at a level much above background to these stimulator cells, a reflection of T cell genetic self-tolerance to these non-MHC moieties. Interestingly, the Mls^a and Mls^c determinants detected on the CE/J stimulator cells in this primary MLR also elicited equally vigorous cell division with appropriate responder populations. Thus, the Mls^a determinant is not unique in its ability to provide a very powerful T cell stimulus. The Mls^c gene products, at least in the context of C58/J and CE/J non-MHC backgrounds, can also induce very high levels of responder cell proliferation in vitro that approach those commonly associated with response to Mls^a.

In agreement with the reports that an Mls^a-specific hybridoma (34) and Mls^a- (but not Mls^c-) specific T cell clones (10, 11) proliferated to MA/My stimulator cells, Mls^c C3H/HeJ T cells that should recognize the Mls^a determinant showed a substantial level of cell division when cultured with normal or GaMD-activated MA/My stimulator cells (Table I, experiments 1 and 2). However, the level of responder cell proliferation elicited across an Mls^a barrier by MA/My stimulator cells was relatively low when compared with other Mls^a-bearing stimulator cells. MA/My splenocytes in these experiments also consistently brought about a low level of Mls^a AKR/J and Mls^{a/c} (AKR × C3H)F₁ T cell proliferation that was above background. MA/My stimulator cells also elicited proliferation

TABLE I
 Analysis of MIs^a and MIs^c stimulatory capacity of splenocytes from selected H-2^k inbred mouse strains

| Stimulator Cells ^a | | Responder Cells ^b | | | | | | |
|---------------------------------------|------|------------------------------|---------|--------------------------------|---------|---------------------------------------|---------|-------------------------------|
| Strain | MIs | AKR/J (MIs ^c MLR) | | C3H/HeJ (MIs ^c MLR) | | (AKR × C3H) _F ₁ | | CByD2F ₁ (H-2 MLR) |
| | | Expt. 1 | Expt. 2 | Expt. 1 | Expt. 2 | Expt. 1 | Expt. 2 | Expt. 1 |
| AKR/J | a | 5,412 ^c | 3,181 | 157,908 | 320,764 | 4,946 | 3,668 | 79,955 |
| C3H/HeJ | c | 17,471 | 84,035 | 2,864 | 9,925 | 5,413 | 6,916 | 104,228 |
| (AKR × C3H) _F ₁ | a, c | 13,606 | 11,897 | 181,983 | 335,712 | 5,677 | 3,192 | NT ^d |
| CBA/J | a, c | 16,467 | 27,355 | 200,133 | 346,568 | 4,204 | 7,217 | 97,799 |
| C58/J | a, c | 174,834 | 306,519 | 173,737 | 290,487 | 7,986 | 8,111 | 99,620 |
| CE/J | a, c | 115,814 | NT | 97,485 | NT | 4,779 | NT | 79,632 |
| MA/My | a | 13,310 | 11,974 | 33,209 | 79,641 | 12,101 | 11,020 | 97,496 |
| RF/J | a, c | 10,391 | 6,923 | 234,789 | 282,757 | 4,813 | 3,362 | 97,682 |
| C57BL/10 | b | 101,230 | 90,130 | 49,376 | 61,009 | 76,674 | 60,267 | 87,442 |
| CByD2F ₁ | a, c | NT | NT | NT | NT | NT | NT | 7,375 |

^a Stimulator cells were normal (nonactivated) splenocytes treated with mitomycin C (experiment 1) or GaMD-treated splenocytes that were irradiated with 3000 r (experiment 2).

^b Responder cells were nylon wool-purified splenic T cells (3×10^5 /well).

^c Values are cpm of mean arithmetic [³H]TdR uptake of quadruplicate cultures.

^d Not tested.

of MIs^{a-c} CBA/J T above background levels (data not shown). These results indicate that, besides encoding an MIs^a determinant, MA/My stimulator cells may also express a poorly stimulatory non-MIs^{a-c} non-MHC Ag.

Like C58/J and CE/J, RF/J stimulator cells were previously determined by the use of MIs-specific T cell clones to present both MIs^a and MIs^c determinants (10, 11). In the primary MLR analysis conducted here, the vigorous proliferation of MIs^c C3H/HeJ T cells triggered by normal mitomycin C-treated or GaMD-activated RF/J stimulators was consistent with the expression of the highly stimulatory MIs^a epitope on these splenocytes (Table I, experiments 1 and 2), in agreement with the results from another laboratory (27). However, the MIs^a AKR/J T cells that should recognize the MIs^c determinant on RF/J stimulator cells showed an extremely low level of proliferation only slightly above background in this and other experiments not shown. Thus an additional experiment was performed to provide confirmation that RF/J stimulator cells were genotypically MIs^{a-c}.

If the genome of parental RF/J mice encodes both of these distinct MIs specificities, T cells obtained from this strain of mouse should not proliferate to MIs^a or MIs^c determinants presented on H-2-compatible prototypic stimulator cells. Furthermore, the F₁ animal obtained by crossing B10.BR (H-2^k, MIs^b) mice that are responsive to both MIs^a and MIs^c determinants with RF/J mice should also be nonresponsive to MIs^a and MIs^c determinants because of genetic self-tolerance. When this experiment was performed (Table II), the lack of responsiveness of RF/J and (B10.BR × RF/J)_F₁ T cells to the prototypic MIs^a, MIs^c, and MIs^{a-c}-bearing stimulator cells was consistent with RF/J mice encoding both MIs^a and MIs^c in their genome. Thus the extremely low amount of MIs^a AKR/J T cell proliferation directed toward RF/J stimulator cells (Table I) is most likely generated by recognition of the very poorly presented MIs^c determinants. This defective ability of RF/J to present MIs^c accounts for the previous report that RF/J and AKR/J are mutually nonstimulatory in a primary MLR (27). However, despite profound differences in MIs-stimulatory capacity, each of these H-2^k stimulator cells effectively presented its allogeneic MHC determinants (Table I, experiment 1). Thus no generalized defect in the presentation of alloantigens existed for any of these stimulator splenocytes.

In time course analyses, across an MIs^a barrier (Fig. 1,

left), it was clear that throughout the culture period C58/J, CE/J, and RF/J stimulator cells elicited the same high level of responder proliferation as prototypic AKR/J and CBA/J stimulator splenocytes. Consistent with previous experiments, MA/My stimulator cells provoked substantially reduced T cell proliferation across the same non-MHC difference during this time frame. When proliferation across an MIs^c barrier (Fig. 1, right) was subsequently examined in a separate experiment, C58/J and CE/J splenocytes elicited substantially better proliferation during the periods of optimal stimulation than did prototypic C3H/HeJ stimulator cells. In other experiments (Table I; Fig. 2), when the MIs^a and MIs^c stimulatory capacities of C58/J and CE/J were compared at the same time, these stimulator cells were found to provoke similarly high levels of T cell proliferation across both these non-MHC barriers. RF/J splenocytes elicited undetectable to barely detectable levels of responder proliferation across an MIs^c difference in this time course study. Thus the examination of nonprototypic MIs^a and/or MIs^c-bearing splenic stimulator cells reveals widely varying differences in the capacity to present both non-MHC moieties. These observations are not compatible with the usually stated position (2-7, 10, 14, 15, 18, 21-35) that equates MIs^a only to highly stimulatory and MIs^c only to poorly/intermediately stimulatory determinants in a primary MLR.

Stimulator cell capacity to elicit different levels of responder proliferation across an MIs^a or MIs^c difference correlates with T cell growth factor activity elaborated in supernatants. Although proliferation assays are frequently used to quantitate T cell activation after exposure to various stimuli, the release of cytokines such as IL-2 also serves as a sensitive measure of T cell activation (40). In the primary MLR, T cell costimulatory molecules, IL-2 and IL-4, are produced and can be detected in the supernatants by bioassay with appropriate indicator cell lines (41).

However, the elaboration of substantial levels of T cell-derived IL-2 has been detected in the absence of proliferation to certain alloantigen-presenting cells of B cell origin (42). Thus, the amount of T cell proliferation and the level of cytokine production may not always parallel one another in every experimental system. Accordingly, the relationship between the differing levels of responder cell proliferation elicited by the various MIs^a and/or MIs^c

TABLE II
The genome of RF/J mice encodes both MIs^a and MIs^c determinants

| Stimulator Cells ^a | | | Responder Cells ^b | | | |
|-------------------------------|-----|------|------------------------------|---|---|--|
| Strain | H-2 | MIs | Cell No. × 10 ⁻⁵ | B10.BR (H-2 ^k , MIs ^b) | RF/J (H-2 ^k , MIs ^{a,c}) | (B10.BR × RF/J)F ₁ (H-2 ^k , MIs ^{b,a,c}) |
| Syngeneic | k | | 1.5 | 7,339 ^c | 3,114 | 2,558 |
| | | | 3 | 1,046 | 3,308 | 4,410 |
| | | | 6 | 1,197 | 4,622 | 3,861 |
| AKR/J | k | a | 1.5 | 116,571 | 2,490 | 2,782 |
| | | | 3 | 147,943 | 4,894 | 4,290 |
| | | | 6 | 124,984 | 4,722 | 3,659 |
| C3H/HeJ | k | c | 1.5 | 18,645 | 5,239 | 4,684 |
| | | | 3 | 26,502 | 6,515 | 7,757 |
| | | | 6 | 40,880 | 9,329 | 7,656 |
| CBA/J | k | a, c | 1.5 | 124,608 | 3,925 | 3,839 |
| | | | 3 | 161,543 | 5,365 | 5,602 |
| | | | 6 | 141,495 | 7,115 | 5,407 |
| B10.D2 | d | b | 1.5 | 46,589 | 76,653 | 82,169 |

^a Stimulator cells were GaMD-treated splenocytes that were irradiated with 3000 r.

^b See legend to Table I.

^c See legend to Table I.

presenting cells and relative amount of T cell growth factor activity (IL-2, IL-4) produced in these primary MLR was explored.

Figure 2A shows the maximal proliferation values of AKR/J (MIs^c MLR) or C3H/HeJ (MIs^c MLR) T cells obtained in a dose response study by using varying numbers (1 to 6 × 10⁻⁵) of mitomycin C-treated, MIs-disparate splenic stimulator cells; the MLR was harvested at 108 h after the initiation of culture. The relative level of responder cell proliferation across an MIs^a or MIs^c barrier triggered by each stimulator population was consistent with the results presented above. In Figure 2B, the proliferation of the IL-2- and IL-4-sensitive HT-2 cell line in response to 48-h supernatants (1 to 4 dilution) from each corresponding MLR is displayed. The level of HT-2 indicator cell proliferation in response to the cytokine-containing supernatants mirrored rather precisely the level of T cell proliferation observed in the original MIs^a- or MIs^c-defined primary MLR. Of particular interest was the RF/J stimulator population that elicited virtually no responder cell division or T cell growth factor activity (IL-2, IL-4) across an MIs^c barrier (in contrast to highly stimulatory CE/J or C58/J splenocytes). However, RF/J stimulator cells were able to provoke very high levels of T cell proliferation and cytokine release across an MIs^a difference. These observations suggest that there may be unique sets of non-MHC regulatory controls that exert separate influences on the presentation of MIs^a or MIs^c determinants expressed by the same stimulator population.

A single dominant non-MHC gene regulates the presentation of MIs^c in the super-stimulatory form. Presentation of MIs^c by the splenocytes from parental BALB.K and C3H/HeJ mice, their F₁, first backcross, and F₂ progeny in a previous study from this laboratory suggested that, besides the well documented role of the MHC in regulating MIs^c stimulatory capacity, multiple non-MHC genes (8) also exert an important influence.

In this investigation, the study of non-MHC genetic influences that regulate the presentation of MIs^c determinants is extended by utilizing parental strains in the segregation analysis that express the super-stimulatory form of MIs^c (C58/J) or poorly present this non-MHC

moiety (BALB.K). When the (BALB.K × C58/J)F₁ animals were generated and their mitomycin C-treated normal splenocytes were used to present MIs^c determinants in a primary MLR, these F₁ stimulator cells consistently approximated the C58/J parental splenocytes over a range of cell concentrations in triggering very high levels of H-2-compatible T cell proliferation (Fig. 3, upper left). Thus the super-stimulatory MIs^c presenting capacity of the (BALB.K × C58/J)F₁ splenocytes differed substantially from the previously studied MIs^c stimulatory capacity of (BALB.K × C3H/HeJ)F₁ splenocytes that was intermediate between BALB.K and C3H/HeJ parental stimulator cells (8).

In a similar experiment, CE/J (MIs^c super-stimulatory) mice were crossed with RF/J mice that were the least capable of any H-2^k strain examined so far in regard to MIs^c presenting ability. Again, mitomycin C-treated splenocytes from the (RF/J × CE/J)F₁ animals closely resembled the MIs^c super-stimulatory parent, CE/J, in their capacity to present this non-MHC determinant (Fig. 3, lower left). Mendelian genetic theory predicts that no intermediate phenotype will occur when the inheritance pattern of a trait is controlled by a single dominant locus. Thus, the results of these two experiments were compatible with presentation of the super-stimulatory form of MIs^c being regulated by a single dominant non-MHC gene. In these experiments, although both BALB.K and RF/J stimulator cells were poor presenters of MIs^c, they showed no impairment in their capacity to present MHC determinants in a primary MLR (Fig. 3, upper and lower right). Splenocytes from an F₁ animal obtained by crossing an MIs^a super-stimulatory strain, CBA/J, and an MIs^a poorly stimulatory strain, MA/My, also more closely resembled the super-stimulatory parent in eliciting vigorous levels of C3H/HeJ T cell proliferation across an MIs^a difference (data not shown). However, the issue of the dominance of the super-stimulatory form of MIs^a in these (CBA/J × MA/My)F₁ stimulator cells is complicated by the observation that MA/My may lack a component of the MIs^a determinant usually expressed by prototype strains (see below).

To test further the hypothesis that a single non-MHC regulatory gene controlled the presentation of the super-


Mls^a MLR
C3H RESPONDERSMls^c MLR
AKR RESPONDERS


Figure 1. Time course of proliferation of responder cells to Mls^a or Mls^c determinants expressed by selected H-2^k stimulator cells. C3H/HeJ (H-2^k, Mls^c) or AKR/J (H-2^k, Mls^a) nylon wool-purified T cells (3×10^5 /well) were cultured with H-2^k-compatible GaMD-treated splenocytes (3 to 6×10^5 /well) in separate experiments to assess their Mls^a (left) or Mls^c (right) stimulatory capacity at 2, 3, 4, and 5 days after the MLR culture was established.

stimulatory Mls^c phenotype. (BALB.K \times C58)_F₁ \times BALB.K first backcross and (BALB.K \times C58)_F₂ mice were generated. Splenocytes from these animals, after mitomycin C treatment, were individually analyzed for Mls^c presenting capacity with AKR/J (Mls^a) responder T cells in a primary MLR in comparison with stimulator cells from parental and F₁ types (Fig. 4). The results indicated that the first backcross animals segregated into two easily detectable phenotypic populations in terms of Mls^c stimulatory capacity. A total of 20 of the 45 first backcross animals (44.4%) resembled parental C58/J and F₁ animals in possessing a potent Mls^c stimulatory capacity; however, the remaining 25 animals (55.6%) demonstrated a poor Mls^c stimulatory ability that resembled the BALB.K parental type. With the 59 F₂ progeny examined, 48 animals

(81.4%) most closely resembled the highly Mls^c stimulatory C58/J and F₁ mice whereas the other 11 animals (18.6%) had the poorly Mls^c stimulatory phenotype resembling the BALB.K parent. χ^2 analysis of the first backcross ($\chi^2 = 0.556$) and F₂ ($\chi^2 = 1.271$) data does not allow rejection of the hypothesis that a single gene regulates the presentation of the super-stimulatory form of the Mls^c determinant at the 5% level of significance. However, the hypothesis that two codominant genes control the expression of super-stimulatory Mls^c can easily be rejected at this level of significance by χ^2 analysis of the first backcross ($\chi^2 = 22.41$) and F₂ ($\chi^2 = 15.45$) stimulatory capacity.

The non-MHC influence responsible for the super-stimulatory form of Mls^c is exerted in splenocytes from

Figure 2. Comparison of the level of responder T cell proliferation elicited with the level of T cell growth factor activity elaborated in an MIs^a or MIs^c-defined MLR triggered by various H-2^b-compatible stimulator cells. AKR/J (H-2^b, MIs^a) or C3H/HeJ (H-2^b, MIs^c) nylon wool-purified T cells (3×10^5 /well) were cultured with normal mitomycin C-treated splenocytes (1 to 6×10^5 /well) of the stimulator strains listed; the MLR was harvested at 108 h after the culture was established, to assess maximal T cell proliferation across an MIs^a (□) or MIs^c (▨) barrier (A). HT-2 cells (4×10^5 /well) were cultured for a 24-h period with the 48-h supernatants (diluted 1/4) from each of the corresponding MLR to assess T cell growth factor activity elaborated across an MIs^a (□) or MIs^c (▨) difference (B).



XID⁺ B cell-defective CBA/N F₁ male animals as well as B cell-normal CBA/N F₁ female littermates. Because B lymphocytes are capable of presenting MIs determinants (32, 35, 39, 43) and may be the cell type in which the non-MHC regulatory genes act, we wished to determine if the non-MHC influence that confers super-stimulatory capacity to MIs^c in the B cell-normal C58/J mice could be operative in the B cell-defective environment of *xid*⁺ splenocyte stimulator cells. Because the frequency of Ig-positive splenocytes in *xid*⁺ CBA/N F₁ male mice is approximately 40% less than that found in their phenotypically B cell-normal female F₁ littermates (44), male and female CBA/N F₁ stimulator cells were depleted of T cells by treatment with anti-Thy 1.2 + C to obtain approximately equivalent numbers of non-T MIs-presenting cells in both groups.

In agreement with a previous report (45), the *xid*⁺ (CBA/N \times C3H/HeJ)F₁ male stimulator splenocytes did not elicit convincing levels of proliferation across an MIs^c difference whereas the lymphoid cell population from phenotypically B cell-normal female F₁ littermates was capable of triggering T cell proliferation across this non-MHC barrier (Table III, experiment 1). In contrast, the *xid*⁺ (CBA/N \times C58/J)F₁ male stimulator cells were capable of triggering a significant level of responder cell proliferation directed toward an MIs^c disparity (Table III, experiment 2). Nevertheless, the splenocytes from the (CBA/N \times C58/J)F₁ female mice more effectively presented both MIs^c and MIs^a determinants than stimulator cells from


the B cell-defective F₁ male animals. It was also consistent with other reports (26) that the splenocytes from adult *xid*⁺ (CBA/N \times C58/J)F₁ male animals elicited comparable levels of proliferation at optimal cell concentrations across an MHC barrier in comparison with the B cell-normal F₁ female littermates.

In regard to the presentation of MIs^a determinants by the *xid*⁺ (CBA/N \times C58/J)F₁ stimulator cells, the splenocytes from the male F₁ animals were less effective stimulator cells across this barrier than they were across the MIs^c barrier (Table III, experiment 2). However, previous experiments (Table I; Figs. 1 and 2) have suggested that independent non-MHC regulation of MIs^a and MIs^c determinants exists for stimulator cells presenting both of these specificities simultaneously. Consequently, it is possible that non-MHC genes in the C58/J background that may control or upregulate the presentation of the MIs^a may be less capable of penetrating or functioning in the *xid*⁺ environment than is the non-MHC gene that enhances the presentation of super-stimulatory MIs^c.

Thus this series of experiments indicated that the non-MHC genetic control that regulated the super-stimulatory form of MIs^c determinants expressed by B cell-normal presenting cells was able to exert its influence in the B cell-defective environment of *xid*⁺ non-T cell stimulator cells. However, this potent non-MHC genetic influence could not totally overcome the *xid* defect in the presentation of the MIs^c specificity.

Parental, non-prototypic, poorly stimulatory MIs^c

Figure 3. Comparison of Mls and H-2 stimulatory capacity of splenocytes from BALB.K, C58/J, and their F₁ as well as RF/J, CE/J, and their F₁. Nylon wool-purified splenic T cells (3×10^5 /well) from AKR/J (H-2^k, Mls^a) mice were utilized to detect the Mls^c-stimulatory capacity of normal mitomycin C-treated splenocytes from C58/J (H-2^k, Mls^a), BALB.K (H-2^k, Mls^a), and their F₁ (upper left) or CE/J (H-2^k, Mls^a), RF/J (H-2^k, Mls^a), and their F₁ (lower left). Similarly purified (BALB/c \times DBA/2)F₁ (H-2^d, Mls^a) or (C57BL/6 \times DBA/2)F₁ (H-2^{b/d}, Mls^a) splenic T cells (3×10^5 /well) were utilized, respectively, to detect the H-2 stimulatory capacity of C58/J, BALB.K, and their F₁ (upper right) or CE/J, RF/J, and their F₁ (lower right).



Mls^c PRESENTING CAPACITY OF STIMULATOR CELLS:

Figure 4. Comparison of Mls^c-stimulatory capacity of splenocytes from parental BALB.K, C58/J, their F₁, F₂, and first backcross. Nylon wool-purified AKR/J (H-2^k, Mls^a) splenic T cells (3×10^5 /well) were cultured with normal mitomycin C-treated splenocytes (6×10^5 /well) from C58/J (H-2^k, Mls^a), BALB.K (H-2^k, Mls^a), (BALB.K \times C58/J)F₁, (F₁ \times BALB.K) first backcross, and (BALB.K \times C58/J)F₂ mice to detect their Mls^c stimulatory capacity. The MLR cultures were harvested after 72 h. The horizontal lines indicate the mean cpm value of T cell proliferation elicited by each stimulator cell group.




TABLE III

Non-MHC regulatory genes exert their influence on the presentation of MIs^c in splenocytes from XID^a B cell-defective CBA/N F₁ male and phenotypically B cell-normal CBA/N F₁ female mice

| Expt. No. | Stimulator Cells ^a | | Responder Cells ^b | | | |
|--------------------------------------|--------------------------------------|------------------------------------|------------------------------|--------------------------------|------------------------------|--------|
| | Strain | Cell No. × 10 ⁻⁵ | AKR/J (MIs ^c MLR) | C3H/HeJ (MIs ^c MLR) | B6D2F ₁ (H-2 MLR) | |
| 1 | Syngeneic | 2 | 5.187 ^c | | | |
| | | 4 | 8.785 | | | |
| | | 6 | 11.874 | | | |
| | (CBA/N × C3H)F ₁ (male) | 2 | 4.968 | | | |
| | | 4 | 9.109 | | | |
| | | 6 | 15.291 | | | |
| | (CBA/N × C3H)F ₁ (female) | 2 | 20.748 | | | |
| | | 4 | 40.051 | | | |
| | | 6 | 49.692 | | | |
| | 2 | Syngeneic | 3 | 2.066 | 2.495 | 1.612 |
| | | | 6 | 2.728 | 2.379 | 1.118 |
| | | (CBA/N × C58)F ₁ (male) | 3 | 28.165 | 7.355 | 39.303 |
| 6 | | | 45.084 | 12.851 | 26.336 | |
| (CBA/N × C58)F ₁ (female) | | 3 | 100.859 | 37.290 | 46.968 | |
| | | 6 | 151.971 | 98.781 | 41.231 | |

^a Stimulator cells were normal splenocytes, treated first with anti-Thy-1.2 + C and then with mitomycin C.

^b See legend to Table I.

^c See legend to Table I.

mouse strains. BALB/c and DBA/2, generate self-tolerance in F₁ progeny to the super-stimulatory form of MIs^c. Several laboratories have demonstrated that multiple unlinked structural genes contribute to the MIs^c genotype in prototypic C3H mice (13-15). Indeed, there is some evidence that different mouse strains may have different numbers of genes associated with MIs^c phenomena (15). Therefore, it cannot be assumed that a given mouse strain currently classified as MIs^c will encode all of the structural genes associated with the MIs^c of prototypic C3H. Accordingly, it was of interest to determine if the MIs^c genetic elements amplified by a single non-MHC gene to super-stimulatory status would also be encoded in the genome of MIs^c nonprototypic and poorly stimulatory (8) BALB/c and DBA/2 mice. To address this point, the proliferation of T cells derived from (AKR/J × B10.D2)F₁ mice that are fully responsive to prototypic or super-stimulatory MIs^c expressed on C3H/HeJ and C58/J mitomycin C-treated splenocytes, respectively,

was compared with the proliferation of H-2^{k/d}-compatible (AKR/J × BALB/c)F₁ and (AKR/J × DBA/2)F₁ responder cells to these stimulator populations (Table IV, experiment 1).

If BALB/c and DBA/2 encode the genetic component of C3H MIs^c that is amplified on C58/J presenting cells, the T cells obtained from the latter two groups of F₁ animals should be unresponsive both to H-2^k-compatible C3H/HeJ and C58/J stimulatory cell because of genetic self-tolerance. Indeed, in this primary MLR, a total lack of responsiveness to C3H/HeJ and C58/J mitomycin C treated splenocytes was observed with (AKR/J × BALB/c)F₁ and (AKR/J × DBA/2)F₁ T cells. However, they did proliferate vigorously to H-2^s-different SJL/J third party stimulator cells. Self-tolerance to super-stimulatory MIs^c was confirmed in another experiment (Table IV, experiment 2), in which the two (AKR/J × C58/J)F₁ × B10.BR backcross animals that typed as super-stimulatory MIs^c were nonstimulatory for (AKR/J

TABLE IV

F₁ animals generated from MIs^c nonprototypic BALB/c or DBA/2 parental mouse strains are self-tolerant to the super-stimulatory form of MIs^c

| Expt. No. | Stimulator Cells ^a | Responder Cells ^b | | |
|-----------|------------------------------------|------------------------------|------------------------------|-----------------------------|
| | | (AKR × B10.D2)F ₁ | (AKR × BALB/c)F ₁ | (AKR × DBA/2)F ₁ |
| 1 | Syngeneic | 5.596 ^c | 5.682 | 5.659 |
| | C3H/HeJ | 51.480 | 5.923 | 10.539 |
| | C58/J | 222.940 | 7.505 | 7.752 |
| | SJL/J | 148.027 | 145.246 | 111.894 |
| 2 | Syngeneic | 3.085 | 4.442 | |
| | C3H/HeJ | 29.888 | 3.823 | |
| | C58/J | 136.245 | 6.281 | |
| | (B10.BR × C58)F ₁ | 130.018 | 4.015 | |
| | (AKR × C58)F ₁ × B10.BR | | | |
| | 1 | 4.904 | 3.322 | |
| | 2 | 7.356 | 7.688 | |
| | 3 | 123.238 | 5.916 | |
| | 4 | 3.964 | 3.374 | |
| | 5 | 122.516 | 3.342 | |
| | 6 | 2.424 | 1.468 | |
| | C57BL/10 | 51.939 | 51.247 | |

^a Stimulator cells were mitomycin C-treated normal splenocytes.

^b See legend to Table I.

^c See legend to Table I.

× BALB/c)F₁ T cells.

The finding that the BALB non-MHC background (that is associated with poor presentation (8) of Mls^c by both Ia^b- and Ia^d-bearing stimulator cells) likely encodes the Mls^c genetic element upregulated on C58/J stimulator cells strengthens the previous contention that it was the action of a single non-MHC regulatory gene in (BALB.K × C58/J)F₁, (BALB.K × C58/J)F₁ × BALB.K backcross and (BALB.K × C58/J)F₂ animals (Fig. 4) that controlled the expression of the super-stimulatory form of Mls^c. In addition, although CBA/J splenocytes usually present Mls^c more poorly (8) than prototypic C3H/HeJ, T cells from the former strain were also found to be unresponsive to Mls^c super-stimulatory C58/J or CE/J splenocytes (data not shown). Taken together, these results suggest that the Mls^c genetic element amplified on C58/J presenting cells by a single non-MHC gene is distributed among prototypic and nonprototypic Mls^c-bearing mouse strains.

Mls^a and Mls^c prototypic mouse strains may express an additional Mls specificity. To confirm earlier observations about the Mls composition of RF/J, CE/J, C58/J, and MA/My mouse strains, T cells were isolated from each and cultured with H-2^k-compatible Mls^a prototypic AKR/J and Mls^c prototypic C3H/HeJ stimulator cells (Table V).

The lack of proliferation of RF/J and CE/J T cells to prototypic Mls^a and Mls^c stimulator cells (Table V, experiments 1 and 2) was consistent with the primary MLR data previously presented (Tables I and II) and the reports using Mls^a-specific clones and Mls^c-specific clones (10, 11) that indicated RF/J and CE/J splenocytes expressed both Mls^a and Mls^c specificities. However, the substantial level of proliferation of C58/J and MA/My T cells to the Mls prototypic stimulator cells with which they were supposedly Mls and H-2 compatible suggested an unanticipated complexity in understanding the Mls genotypes not only of these two responder cells but also the AKR/J (Mls^a) and C3H/HeJ (Mls^c) prototypic stimulator cells (Table V, experiments 3 and 4).

Because Mls^a-specific clones and Mls^c-specific clones (10, 11) as well as Mls^a (AKR/J) and Mls^c (C3H/HeJ), but not Mls^{a,c} ((AKR × C3H)F₁), unprimed T cells (Table I) proliferated vigorously on C58/J stimulator cells, it seemed most likely that both Mls^a and Mls^c determinants were expressed on C58/J splenocytes. Other Mls^{a,c} F₁ T

cells, (AKR/J × BALB/c)F₁ and (AKR/J × DBA/2)F₁ (Table IV) as well as CBA/J (data not shown), also did not respond to the potent non-MHC specificities presented by C58/J lymphoid cells. Thus the convincing proliferation of Mls^{a,c} C58/J T cells to Mls^a and Mls^c prototypic stimulator cells could represent the recognition of a newly defined Mls specificity.

The proliferation of Mls^c C3H/HeJ heterogeneous T cells (Table I) and cloned Mls^a-specific (but not cloned Mls^c-specific) T cells (10, 11) in response to MA/My stimulator cells was consistent with the expression of Mls^a but not Mls^c moieties on MA/My splenocytes. The response of Mls^a MA/My T cells to Mls^a AKR/J stimulator cells may indicate that the prototypic Mls^a determinant contains a component not shared with MA/My.

Mitomycin C-treated normal splenocytes (like the GaMD-activated irradiated stimulator cells used in Table V) also elicited these same unexpected C58/J and MA/My T cell non-MHC MLR proliferative responses (data not shown).

DISCUSSION

A commonly held contention in many previously published Mls studies (2-7, 10, 14, 15, 18, 21-35) is that the unprimed heterogenous T cell response to the Mls^c determinants is significantly less vigorous than it is to the Mls^a gene products. This view is based, however, only on the analysis of stimulator cells from the original prototypic Mls^c-bearing mouse strains, C3H and A/J, identified by Festerstein (2, 3) over a decade ago. The primary MLR-stimulatory capacity of Mls^c and Mls^a determinants expressed on strains of mice recently identified to encode these non-MHC determinants, by use of Mls-specific T cell clones (10, 11), has not been extensively explored.

Because non-MHC (in addition to MHC) genes can cause substantial variation in Mls-presenting ability among inbred mouse strains (8), we questioned whether the accepted characterization of Mls^c as a weakly or intermediately stimulatory or Mls^a as highly stimulatory would hold true upon closer scrutiny of nonprototypic Mls-bearing mouse strains.

Across an Mls^c barrier there was an impressive gradient of MLR stimulatory potential displayed with splenocytes obtained from the nonprototypic mouse strains. At one extreme, RF/J stimulator cells were virtually incapable of presenting this non-MHC specificity in a primary

TABLE V
Analysis of RF/J, CE/J, C58/J, and MA/MyJ T cell responsiveness to prototypic Mls^a and Mls^c stimulator cells

| Expt. No. | Responder Cells ^a | | | Stimulator Cells ^b | | |
|-----------|------------------------------|------|--------------------|-------------------------------|-------------------------|----------------------------|
| | Strain | Mls | Syngeneic | AKR/J (Mls ^a) | C3H (Mls ^c) | B10.D2 (H-2 ^d) |
| 1 | B10.BR | b | 4.435 ^c | 105.178 | 26.089 | 64.802 |
| | RF/J | a, c | 7.600 | 6.551 | 9.272 | 85.968 |
| 2 | B10.BR | b | 4.711 | 182.069 | 25.883 | 61.676 |
| | CE/J | a, c | 10.851 | 7.928 | 5.858 | 99.749 |
| 3 | B10.BR | b | 2.949 | 225.725 | 27.286 | 106.212 |
| | C58/J | a, c | 4.959 | <u>44.261^d</u> | <u>30.926</u> | 73.797 |
| 4 | B10.BR | b | 2.735 | 164.582 | 65.427 | 78.961 |
| | MA/MyJ | a | 4.852 | <u>54.321</u> | 72.447 | 77.498 |

^a Responder cells were nylon wool-purified splenic T cells.

^b Stimulator cells were GaMD-treated splenocytes that were irradiated with 3000 r.

^c See legend to Table I.

^d Underlining indicates the unanticipated proliferation of responder cells to the Mls prototypic stimulator cell that shares the Mls specificity with the responder.

MLR as measured by responder T cell proliferation or in vitro elaboration of T cell growth factor activity (IL-2, IL-4). In marked contrast, C58/J and CE/J splenocytes were capable of triggering extremely high levels of responder cell division and cytokine production in an Mls^c-defined primary MLR. The amount of T cell proliferation and T cell growth factor activity elicited by the latter two stimulator populations across an Mls^c barrier reached levels commonly associated with the Mls^a determinant. Prototypic C3H/HeJ stimulator cells fell in between very poorly stimulatory RF/J and super-stimulatory C58/J and CE/J in Mls^c presenting capacity.

Across the "historic" super-stimulatory Mls^a barrier, H-2^b MA/My stimulator cells had a rather modest capacity to stimulate H-2-compatible T cell proliferation or T cell growth factor production when compared with prototypic Mls^a-bearing AKR/J and CBA/J or less well studied C58/J and CE/J splenocytes. Among H-2^b mouse strains, we previously observed that LT/ChReSv splenocytes presented Mls^a determinants less effectively than prototypic DBA/2 stimulator cells (8).

Thus for both an Mls^c difference and an Mls^a difference, these Mls nonprototypic mouse strains provided important examples of Mls stimulatory potential (as a result of the influence of the non-MHC environment) that was in sharp contrast to that usually associated with the AKR/J (Mls^a) and C3H/HeJ (Mls^c) prototypic strains.

Although the T cell repertoire appears to contain fewer cells responsive to Mls^c (V β 3⁺) than Mls^a (V β 6⁺ and V β 8.1⁺) (16-18, 19), equivalent levels of responder proliferation (Table I; Fig. 2) and cytokine production (Fig. 2) were elicited by super-stimulatory Mls^a and super-stimulatory Mls^c-bearing splenocytes. Thus one might speculate that the non-MHC gene that controls the super-stimulatory forms of Mls^c may act by increasing the intensity of this signal delivered to V β 3⁺ T cells and thereby allow very rapid expansion of this responder population.

Clearly diverse genetic regulatory mechanisms are operating to control the in vitro presentation of Mls^c in these different non-MHC environments. This variety of non-MHC genetic influences is exemplified by the action of: a) multiple non-MHC IR genes that control the presentation of the weakly to intermediately stimulatory Mls^c determinants in the first backcross and F₂ progeny derived from BALB.K and C3H/HeJ parental strains (8), b) a dominant single non-MHC gene that controls the presentation of the super-stimulatory form of Mls^c present on C58/J (and probably CE/J) stimulator cells (Fig. 4), and c) the recessive non-H-2-determined genetic influence that brings about the virtual elimination of Mls^c-stimulating ability for RF/J splenocytes (Fig. 3).

Differing, but not necessarily mutually exclusive, mechanisms might account for this non-MHC-regulated broad spectrum of Mls^c-stimulatory capacity for presenting cells with fully permissive H-2 haplotypes. Because identical, or at least highly cross-reactive, immunodominant non-H-2 Ag capable of stimulating the generation of cytotoxic lymphocytes were mapped to independently segregating loci in different recombinant inbred mouse strains (46), the possibility may exist that the genes encoding Mls^c or Mls^a determinants also exhibit a certain "mobility" and are located on different chromosomes in different mouse strains. If this is true, the radically dif-

fering non-MHC milieu of enhancer, promoter, or modifier genes (associated with different chromosomal locations) that influence the stimulation of transcription and tissue-specific gene expression could cause Mls-presenting capacity to vary remarkably among genetically disparate strains of H-2-compatible mice. Alternatively, if the alleles of a given Mls gene uniformly map to the same chromosomal location for all strains of mice, local variation in the structure or positioning of enhancer, promoter, or (even nonlinked) modifier sequences could bring about differences in expression and thus presentation of these non-MHC specificities.

In mice that have a permissive H-2 but low or virtually undetectable Mls^c stimulatory capacity, other self-Ag peptides might be present that have a higher affinity for the binding site of class II MHC molecules and thus effectively compete out the the presentation of Mls Ag. Such competition for interaction with Ia molecules has been described for immunogenic hen egg lysozyme peptides (47). Furthermore, non-MHC-regulated genetic differences that in vitro could bring about inappropriate shedding or processing of Mls moieties might also contribute to the poor Mls-presenting capacity that is reproducibly associated with certain mouse strains having fully permissive H-2 haplotypes. The mixing, in a primary MLR, of stimulator cells that have a permissive MHC yet elicit extremely low levels of response across an Mls^c barrier with H-2-compatible stimulators that trigger extremely high levels of T cell proliferation across this non-MHC difference, e.g., RF/J with CE/J, never gave an indication that the induction of suppressor cells played a role in eliminating the response to Mls^c determinants (data not shown).

Three other laboratories have addressed the issue of the genetic control of Mls^c determinants by using backcross analysis (13-15). Click and Adelman (13) and Pullen et al. (14) concluded that three independently segregating loci control phenomena associated with prototypic Mls^c of the C3H mouse strain. However, Abe and Hodes (15) have presented evidence that at least two genes are involved in the expression of Mls^c encoded in C3H/HeJ mice. Interestingly, the latter investigators also found that the expression of Mls^c by CBA/J stimulator cells may be regulated by a single gene (15).

In contrast to those three studies, the segregation analysis conducted in the present as well as the previous (8) investigation from this laboratory, dealing with non-MHC regulation of Mls^c, has utilized first backcross and F₂ animals derived from parental strains that both encode Mls^c structural genes (with the exception of Table IV, experiment 2). The protocols for the experiments were designed in this way in order to observe more clearly the action of non-MHC regulatory influence on the Mls^c gene products by minimizing structural gene dose effects that might be encountered in Mls^c heterozygotes. However, it is not known for certain if RF/J and CE/J mice as well as C58/J, BALB.K, their F₁, F₂, and first backcross (Fig. 4) each encode an identical number of Mls^c structural genes, located at precisely the same chromosomal locations as in the C3H prototype strain. Nevertheless, the existence of a single dominant C58/J non-MHC regulatory gene that controls presentation/expression of super-stimulatory Mls^c provides the most economical explanation for a) the dominance of the super-stimulatory Mls^c

phenotype in (MIs^c poorly stimulatory × MIs^c super-stimulatory)F₁ animals (Fig. 3). b) the χ^2 analysis of MIs^c stimulatory potential of splenocytes from (BALB.K × C58)F₁ × BALB.K and (BALB.K × C58)F₂ progeny (Fig. 4). and c) the observation that F₁ animals generated from MIs^c poorly stimulatory and nonprototypic (8) BALB/c mice were fully self-tolerant to the super-stimulatory form of MIs^c (Table IV).

The potency of the enhancing effect of the single non-MHC gene encoded in the C58/J background on MIs^c presentation is further demonstrated by the augmented and easily detected capacity of B cell-defective xid⁺ (CBA/N × C58/J)F₁ male non-T splenocytes to present this non-H-2 moiety in comparison with xid⁺ (CBA/N × C3H/HeJ)F₁ male stimulator cells (Table III).

Although C58/J and CE/J stimulator cells provide extremely interesting examples of non-MHC-controlled enhancement of a cell-surface structure, further study of RF/J stimulator cells that also possess a permissive H-2 haplotype yet fail to present effectively their encoded MIs^c determinants may also yield valuable information about negative pathways of MIs gene regulation. Consistent with the classification of RF/J as MIs^{a,c}, RF/J and (B10.BR × RF/J)F₁ T cells were unresponsive to MIs^a prototypic AKR/J, MIs^c prototypic C3H/HeJ, and MIs^{a,c} prototypic CBA/J splenocytes in a primary MLR (Table II). However, we also observed some variation from experiment to experiment in the response of RF/J and (B10.BR × RF/J)F₁ T cells to H-2^k and MIs^{a,c}-compatible CE/J and C58/J stimulator cells (data not shown). The occasional low level responses to the latter stimulator cells that express the super-stimulatory form of MIs^c might mean that RF/J mice contained low levels of V β 3⁺ T cells. Interestingly, Pullen et al. (14) have noted a higher number of V β 3⁺ T cells among MIs-2⁺ AKXD RI strains that were the poorest presenters of this non-MHC specificity.

Primary non-MHC MLR proliferative results with T cells from MIs nonprototypic mouse strains suggest a possible need for further revision of current MIs concepts.

First, the positive response of MA/My T cells to H-2^k, MIs^a-compatible (and prototypic) AKR/J stimulator cells was particularly intriguing. Although the MIs^a gene product was originally reported to be encoded by a single gene (48), we are currently investigating the possibility that the prototypic MIs^a-defined MLR (B10.BR or C3H/HeJ anti-AKR/J) can be further delineated into responses to several non-MHC specificities: a) one shared by MA/My and AKR/J and b) the other present only on AKR/J stimulator cells and recognized by MA/My T cells. Based on the study of the distribution of MIs^a in (BALB/c × DBA/2)F₂ animals, other investigators previously proposed that MIs^a is encoded by two separate loci (12).

Second, the substantial C58/J (H-2^k, MIs^{a,c}) primary T cell response to H-2-compatible AKR/J (MIs^a) and C3H/HeJ (MIs^c) splenocytes was also unanticipated. Interestingly, the specificity recognized by C58/J T cells is very widely distributed among inbred mouse strains and is well expressed even by certain prototypic MIs^b (so-called nonstimulatory) presenting cells; this C58/J T cell response may identify a newly defined MIs moiety (J. J. Ryan, H. B. LeJeune, J. J. Mond, and F. D. Finkelman, manuscript in preparation).

Finally, the usual formulation that blanketly categorizes MIs^a and MIs^c Ag as highly or poorly/intermediately stimulatory, respectively, obscures the critical participation of non-MHC genes in regulating the level of strain-specific expression and presentation of MIs specificities. In their most impressive modes of action, non-MHC regulatory genes can virtually eliminate or substantially enhance the presentation of these Ag to unprimed T cells. The ultimate goal of current research must be to characterize biochemically the members of the MIs "family" of molecules and clone the genes that encode them. Based on experiments incorporated in this study, we would predict that effective in vitro functional analysis of isolated MIs genes or gene products could be compromised without due consideration of potentially dramatic and different non-MHC regulatory influences that may be uniquely associated with each presenting cell population examined.

Acknowledgments. The authors thank Drs. Ryo Abe, Robert Hartzman, and Richard Hodes for critical review of this manuscript and valuable discussions during the course of the experiments. The authors also thank Ms. Joann Harrigan for excellent editorial assistance.

REFERENCES

1. Festenstein, H. 1966. Antigenic strength investigated by mixed cultures of allogeneic mouse spleen cells. *Ann. N. Y. Acad. Sci.* 129:567.
2. Festenstein, H. 1974. Pertinent features of M locus determinants including revised nomenclature and strain distribution. *Transplantation* 18:555.
3. Festenstein, H. 1976. The MIs system. *Transplant. Proc.* 8:339.
4. Abe, R., J. J. Ryan, and R. J. Hodes. 1987. MIs is not a single gene; allelic system: different stimulatory MIs determinants are the products of at least two nonallelic, unlinked genes. *J. Exp. Med.* 166:1150.
5. Abe, R., J. J. Ryan, F. D. Finkelman, and R. J. Hodes. 1987. T-cell recognition of MIs: T-cell clones demonstrate polymorphism between MIs^a, MIs^b, and MIs^c. *J. Immunol.* 138:373.
6. Ryan, J. J., J. J. Mond, and F. D. Finkelman. 1987. The MIs^a-defined primary mixed lymphocyte reaction: a composite response to MIs^a and MIs^c determinants. *J. Immunol.* 138:4085.
7. Abe, R., J. J. Ryan, and R. J. Hodes. 1987. Clonal analysis of the MIs system. A reappraisal of polymorphism and allelism among MIs^a, MIs^b, and MIs^c. *J. Exp. Med.* 165:1113.
8. Ryan, J. J., J. J. Mond, and F. D. Finkelman. 1988. Genetic analysis of the presentation of minor lymphocyte stimulating determinants. I. Combined importance of MHC and non-MHC influences. *J. Immunol.* 141:1063.
9. Abe, R., and R. J. Hodes. 1988. The expression of MIs^c determinants on MIs^a, MIs^b, and MIs^c prototypic strains. *Immunogenetics* 28:221.
10. Abromson-Leeman, S. R., J. C. Laning, and M. E. Dorf. 1988. T cell recognition of MIs^a determinants. *J. Immunol.* 140:1726.
11. Abromson-Leeman, S. R., J. C. Laning, J. Crowell, and M. E. Dorf. 1988. The relationship of MIs^a to MIs^c. *J. Immunogenet.* 15:21.
12. Click, R. E., M. M. Azar, and V. E. Anderson. 1982. Immune responses *in vitro*. XII. Two independently segregating loci control MIs^a product(s). *J. Immunol.* 128:1502.
13. Click, R. E., and A. Adelman. 1988. Multigene control of MIs^c. *Immunogenetics* 28:412.
14. Pullen, A. M., P. Marrack, and J. W. Kappler. 1989. Evidence that MIs-2 antigens which delete V β 3⁺ T cells are controlled by multiple genes. *J. Immunol.* 142:3033.
15. Abe, R., and R. J. Hodes. 1989. Properties of the MIs system: a revised formulation of MIs genetics and an analysis of T-cell recognition of MIs determinants. *Immunol. Rev.* 107:5.
16. Kappler, J. W., V. Staerz, J. White, and P. C. Marrack. 1988. Self-tolerance eliminates T-cells specific for MIs-modified products of the major histocompatibility complex. *Nature* 332:35.
17. Abe, R., M. S. Vacchio, B. Fox, and R. J. Hodes. 1988. Preferential expression of T-cell receptor V α 3 gene by MIs^c reactive T cells. *Nature* 335:827.
18. MacDonald, H. R., R. Schneider, R. K. Lees, R. C. Howe, H. Acha-Orbea, H. Festenstein, R. M. Zinkernagel, and H. Hengartner. 1988. T-cell receptor V α use predicts reactivity and tolerance to MIs^a-encoded antigens. *Nature* 332:40.
19. Pullen, A. M., P. Marrack, and J. W. Kappler. 1988. The T-cell repertoire is heavily influenced by tolerance to polymorphic self-

- antigens. *Nature* 335:796.
20. Janeway, C. A., Jr., E. A. Lerner, J. M. Jason, and B. Jones. 1980. T-lymphocytes responding to Mls-locus antigens are Lyt-1⁺, 2⁺, and I-A restricted. *Immunogenetics* 10:481.
 21. Molnar-Kimber, K. L., S. R. Webb, J. Sprent, and D. B. Wilson. 1980. T-cell lines with dual specificity for strong Mls and H-2 determinants. *J. Immunol.* 125:2643.
 22. Molnar-Kimber, K. L., and J. Sprent. 1981. Evidence that strong Mls determinants are nonpolymorphic. *Transplantation* 31:376.
 23. Janeway, C. A., Jr., P. J. Conrad, J. Tite, B. Jones, and D. B. Murphy. 1983. Efficiency of antigen presentation differs in mice differing at the Mls locus. *Nature* 306:80.
 24. Ryan, J. J., J. J. Mond, F. D. Finkelman, and I. Scher. 1983. Enhancement of the mixed lymphocyte reaction by *in vivo* treatment of stimulator spleen cells with anti-IgD antibody. *J. Immunol.* 130:2534.
 25. Macphail, S., and O. Stutman. 1984. Independent inhibition of IL2 synthesis and cell proliferation by anti-Ia antibodies in mixed lymphocyte responses to Mls. *Eur. J. Immunol.* 14:318.
 26. Webb, S. R., D. E. Mosier, D. B. Wilson, and J. Sprent. 1984. Negative selection *in vivo* reveals expression of strong Mls determinants in mice with x-linked immunodeficiency. *J. Exp. Med.* 160:108.
 27. Janeway, C. A., Jr., and M. E. Katz. 1985. The immunobiology of the T cell response to Mls-locus-disparate stimulator cells. I. Unidirectionality, new strain combinations, and the role of Ia antigens. *J. Immunol.* 134:2057.
 28. Katz, M. E., and C. A. Janeway, Jr. 1985. The immunobiology of T-cell responses to Mls-locus-disparate cells. II. Effects of Mls-locus-disparate stimulator cells on cloned, protein antigen-specific, Ia-restricted T-cell lines. *J. Immunol.* 134:2064.
 29. Lynch, D. H., R. E. Gress, B. W. Needleman, S. A. Rosenberg, and R. J. Hodes. 1985. T-cell responses to Mls determinants are restricted by cross-reactive MHC determinants. *J. Immunol.* 134:2071.
 30. Macphail, S., S. T. Ishizaka, M. J. Bykowski, E. C. Lattine, and O. Stutman. 1985. Specific neonatally induced tolerance to Mls locus determinants. *J. Immunol.* 135:2967.
 31. Webb, S., J. Hu, I. MacNeil, P. Marrack, J. Sprent, and D. Wilson. 1985. T cell receptors for response to Mls determinants and allo-H-2 determinants appear to be encoded on different chromosomes. *J. Exp. Med.* 161:269.
 32. Webb, S. R., J. H. Li, D. B. Wilson, and J. Sprent. 1985. Capacity of small B cell-enriched populations to stimulate mixed lymphocyte reactions: marked differences between irradiated vs. mitomycin C-treated stimulators. *Eur. J. Immunol.* 15:92.
 33. Ryan, J. J., D. W. Miner, J. J. Mond, F. D. Finkelman, and J. N. Woody. 1987. Regulation of the *in vitro* presentation of minor lymphocyte stimulating determinants by major histocompatibility complex-encoded immune response genes. *J. Immunol.* 138:2392.
 34. Webb, S. R., A. Okamoto, and J. Sprent. 1988. Analysis of T hybridomas prepared from a T cell clone with three specificities. Recognition of self + X and anti-H-2 determinants segregates from recognition of Mls^a determinants. *J. Immunol.* 141:1828.
 35. Webb, S. R., A. Okamoto, Y. Ron, and J. Sprent. 1989. Restricted tissue distribution of Mls^a determinants: stimulation of Mls^a-reactive T cells by B cells but not by dendritic cells or macrophages. *J. Exp. Med.* 169:1.
 36. Julius, M. H., E. Simpson, and L. A. Herzenberg. 1973. A rapid method for the isolation of functional thymus-derived lymphocytes. *Eur. J. Immunol.* 3:645.
 37. Kupper, T., P. Flood, D. Coleman, and M. Horowitz. 1987. Growth of an interleukin 2/interleukin 4-dependent T cell line induced by granulocyte-macrophage colony-stimulating factor (GM-CSF). *J. Immunol.* 138:4288.
 38. Finkelman, F. D., S. W. Kessler, J. F. Mushinski, and M. Potter. 1981. IgD secreting murine plasmacytomas: identification and partial characterization of two IgD myeloma proteins. *J. Immunol.* 126:680.
 39. Ryan, J. J., C. B. Thompson, J. J. Mond, and F. D. Finkelman. 1988. Augmented *in vitro* presentation of Mls determinants after anti-immunoglobulin-induced B cell activation: ontogeny and role of purified B cells. *J. Immunogenet.* 15:121.
 40. Kappler, J. W., B. Skidmore, J. White, and P. Marrack. 1981. Antigen inducible, H-2 restricted, interleukin-2 producing T cell hybridomas: lack of independent antigen and H-2 recognition. *J. Exp. Med.* 153:1198.
 41. Puré, E., K. Inaba, and J. Metlay. 1988. Lymphokine production by murine T cells in the mixed leukocyte reaction. *J. Exp. Med.* 168:795.
 42. McKean, D. J., A. Nilson, B. N. Beck, S. B. Mizel, and B. S. Handwerker. 1985. Characterization of murine T cell activation signals produced by B lymphoma cells. *J. Immunol.* 134:2484.
 43. Molina, I. J., N. A. Cannon, R. Hyman, and B. T. Huber. 1989. Macrophages and T cells do not express Mls^a determinants. *J. Immunol.* 143:39.
 44. Scher, I., A. Ahmed, D. M. Strong, A. D. Steinberg, and W. E. Paul. 1975. X-linked B-lymphocyte immune defect in CBA/HN mice. I. Studies on the function and composition of spleen cells. *J. Exp. Med.* 141:788.
 45. Ahmed, A., and I. Scher. 1976. Studies on non-H-2-linked lymphocyte-activating determinants. II. Nonexpression of Mls determinants in a mouse strain with an X-linked B lymphocyte immune defect. *J. Immunol.* 117:1922.
 46. Wettstein, P. J., and M. P. Colombo. 1987. Immunodominance in the T cell response to multiple non-H-2 histocompatibility antigens. IV. Partial distribution and mapping of immunodominant antigens. *J. Immunol.* 139:2166.
 47. Adorini, L., E. Appella, G. Doria, and Z. A. Nagy. 1988. Mechanism influencing the immunodominance of T cell determinants. *J. Exp. Med.* 168:2091.
 48. Festenstein, H. 1973. Immunogenetic and biological aspects of *in vitro* lymphocyte allotransformation (MLR) in the mouse. *Transplant. Rev.* 15:62.

| | |
|---------------|-------------------------------------|
| Accession No. | |
| NTIS GRA&I | <input checked="" type="checkbox"/> |
| DTIC TAB | <input type="checkbox"/> |
| Unannounced | <input type="checkbox"/> |
| Justification | |
| By | |
| Distribution/ | |
| Availability | |
| Price | |
| A-1 20 | |

